Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
P/E Ratio
--
P/B Ratio
0.05
Industry P/E
--
Debt to Equity
0
ROE
-0.24 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-415.83
CFO
$130.71 Mln
EBITDA
$647.33 Mln
Net Profit
$-990.85 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
| -97.08 | -56.86 | -97.16 | -97.50 | -83.15 | -80.06 | -59.41 |
|
BSE Sensex*
| 2.05 | 3.83 | 4.35 | 8.29 | 11.76 | 20.17 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
| -1.59 | -67.78 | -42.28 | -66.17 | -86.91 | -27.24 | 14.10 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple... sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. Read more
Founder, CEO, President & Director
Dr. Ron Cohen M.D.
Founder, CEO, President & Director
Dr. Ron Cohen M.D.
Headquarters
Pearl River, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Acorda Therapeutics Inc (ACOR) stood at $ 193 Mln as on 31-Mar-24
The share price of Acorda Therapeutics Inc (ACOR) is $0.44 (NASDAQ) as of 10-May-2024 09:30 EDT. Acorda Therapeutics Inc (ACOR) has given a return of -83.15% in the last 3 years.
Acorda Therapeutics Inc (ACOR) has a market capitalisation of $ 1 Mln as on 10-May-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Acorda Therapeutics Inc (ACOR) is 0.05 times as on 10-May-2024, a 98% discount to its peers’ median range of 2.20 times.
Since, TTM earnings of Acorda Therapeutics Inc (ACOR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Acorda Therapeutics Inc (ACOR) and enter the required number of quantities and click on buy to purchase the shares of Acorda Therapeutics Inc (ACOR).
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
The CEO & director of Dr. Ron Cohen M.D.. is Acorda Therapeutics Inc (ACOR), and CFO & Sr. VP is Dr. Ron Cohen M.D..
There is no promoter pledging in Acorda Therapeutics Inc (ACOR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Acorda Therapeutics Inc. (ACOR) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-7.72
|
|
Net Margin(%)
|
-340.28
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Acorda Therapeutics Inc (ACOR) was $-9 Mln.
$--
(
